RAFAEL HOLDINGS, INC. Deferred Foreign Income Tax Expense (Benefit)
RAFAEL HOLDINGS, INC. (RFL) reported Deferred Foreign Income Tax Expense (Benefit) of -$73.00 thousand for the 12-month period ending 2024-07-31, per its 10-K filed 2025-10-29.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2025-10-29
- RAFAEL HOLDINGS, INC. deferred foreign income tax expense (benefit) for fiscal 2024 was -$73.00K.
- RAFAEL HOLDINGS, INC. deferred foreign income tax expense (benefit) for fiscal 2020 was -$18.00K, a 194.74% decline from fiscal 2019.
- RAFAEL HOLDINGS, INC. deferred foreign income tax expense (benefit) for fiscal 2019 was $19.00K.
- RAFAEL HOLDINGS, INC. deferred foreign income tax expense (benefit) for fiscal 2017 was -$6.00K, a 135.29% decline from fiscal 2016.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month | Deferred Foreign Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2024-07-31 | -$73.00K 10-K · filed 2025-10-29 | |
| 2020-07-31 | -$18.00K 10-K · filed 2021-10-18 | |
| 2019-07-31 | $19.00K 10-K · filed 2020-10-29 | -$19.00K 10-K · filed 2019-10-04 |
| 2017-07-31 | -$6.00K 10-K · filed 2018-10-15 | |
| 2016-07-31 | $17.00K 10-K · filed 2018-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |